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Introduction
Hepatocellular carcinoma (HCC) has become one of the most common malignancy and lethal neoplasm in china [1] . Although roles of multiple oncogenes and (or) tumor suppressor in the development of HCC have been characterized [2] , its molecular mechanisms remain to be elucidated.
DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1), is an orphan nuclear receptor and plays fundamental roles in the steroidogenesis [3, 4] . In human, several reports indicate that DAX-1 gene mutations are tightly linked to congenital adrenal hypoplasia and primary adrenal insufficiency [5, 6] . Besides, DAX-1 was also identified to participate in human cancers, including adrenocortical, pituitary, endometrial, and ovarian tumors [7] . For instance, DAX-1 overexpression could inhibit estrogen-dependent breast cancer cell proliferation through down-regulating aromatase expression [8] . Besides, DAX-1 could interact with and inhibit the nuclear localization of androgen receptor in prostate cancer [9] . Therefore, abnormal expression of DAX-1 might be involved in the pathogenesis of several human cancers. However, whether DAX-1 participates in the progression of HCC remains largely unknown.
In the present study, we found that DAX-1 expression was down-regulated in HCC tissues and cell lines. Overexpression of DAX-1 inhibited, while its deficiency using small interfering RNA (siRNA) promoted proliferation, invasion and metastasis of hepatoma cells. Furthermore, we discovered that DAX-1 played a role in HCC development through regulation of Wnt/β-Catenin signaling. Therefore, our results suggest a novel role of DAX-1 in the regulation of HCC development.
Material and Methods

Tissue samples
Primary hepatocellular carcinoma tissues, adjacent normal liver tissues were collected from routine therapeutic surgery at our department. All samples were obtained with informed consent and approved by our hospital.
Cell culture
All cell lines used were purchased from The Cell Bank of Type Culture Collection of Chinese Academy of Sciences (CAS, Shanghai, China), and cultured in Dulbecco modified Eagle's medium supplemented with 10% fetal calf serum, 100 IU/ml penicillin and 100 mg/ml streptomycin. Cells were incubated at 37℃ under 5% CO 2 humidified atmosphere.
BrdU incorporation and Cell-cycle assays
For BrdU incorporation assays, a cell proliferationenzyme-linked immunosorbent assay kit (Beyotime, Shanghai, China) was employed to analyze the incorporation of BrdU during DNA synthesis following the manufacturer's protocols. For cell-cycle assays, cells were labeled for 15 min with PI and immediately analyzed by flow cytometry. Histograms represent the percentage of cells in each phase of the cell cycle (G0/G1, S and G2/M).
Cell migration and invasion assays
Cell migration and invasion were analyzed using Transwell migration and extracellular matrix-coated invasion chambers (Millipore, CA, USA) according to the manufacturer's instructions. In short, cells were plated into the top well of a Transwell migration chamber (for migration assay) or an extracellular matrixcoated invasion chamber (for invasion assay). After 24 hours incubation, the non-migrating/non-invading cells were removed with a cotton swab, and the migrating/invading cells on the underside of the membrane were stained with cell stain solution (Millipore) for 15 minutes. After washed 2 times with PBS, the stain of each membrane was removed with 100 mL extraction buffer (Millipore) and quantitated with a colorimetric microplate reader at 570 nm. Cells were seeded on to 6-well plates then transfected with 20nM siGENOME non-targeting siRNA, human DAX-1 (5'-GCACGUGGCU CCUUAGCGAU-3', Dharmacon, USA). Total RNAs were isolated from tissues or cells by TRIzol reagent, and reverse transcriptions were performed by Takara RNA PCR kit (Takara, Dalian, China) following the manufacturer's instructions. In order to quantify the transcripts of the interest genes, real-time PCR was performed using a SYBR Green Premix Ex Taq (Takara, Japan) on Light Cycler 480 (Roche, Switzerland). PCR conditions included an initial holding period at 95℃ for 5 min, followed by a twostep PCR program consisting of 95℃ for 5 s and 60℃ for 30s for 45 cycles. The primer sequences were listed as following: DAX-1 (Sense:5'-AGCACAAATCAAGCGCAGG-3',Antisense:5'-GAAGCGCAGCGTCTTCAAC-3'); c-Myc ( 
Immunoprecipitation and Western blot
Cells were harvested, resuspended in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.5% TRITON X-100)and protease inhibitors. Lysates were incubated with 4 μg of indicated antibodies or IgG overnight at 4°C with gentle inversion. Protein A/G beads were added for additional 6 hr at 4°C. Beads containing immune complexes were washed with 0.8 ml ice cold lysis buffer for three times. Precipitates were denatured in Laemmli (gel loading) buffer at 99°C for 10 min. For western blot analysis, cells were harvested by trypsinization, lysed in 2 x Laemmli buffer (100 mM Tris-HCl at pH 6.8, 200 mM DTT, 4% SDS [w/v], 20% glycerol, 0.05% bromophenol blue), denatured for 10 min at 80°C, sheared with an insulin syringe, and resolved on SDS/PAGE gels. After immunoblotting, the membranes were blocked in PBS/0.1% Tween-20 with 5% nonfat dry milk, and primary antibodies were incubated in PBS/0.1% Tween-20 with 0.1%-5% nonfat dry milk. Antibodies directed against DAX-1, β-Catenin, Cyclin D1 and Cyclin E were purchased from Abcam Company (USA). Anti-GAPDH was obtained from Santa Cruz Biotechnology (USA).
Xenograft tumor growth in nude mice 4 weeks old, male BALB/c nude mice were purchased from the Experimental Animal Center of the China Medical University. Approximately 6x10 5 Hep3B cells stably overexpressing DAX-1 or empty vector were injected subcutaneously to the skin under the front legs of the mice. The mice were observed over 4 weeks for tumor formation. Then all the mice were euthanized and the tumor tissues were removed by surgical excision. The tumors were recovered and the wet weights of each tumor were determined. The experiments were performed using six mice per group.
Statistical Analysis
All data are presented as mean ± SEM. Statistical differences were determined by a two-tailed t test. Statistical significance is displayed as * (P < 0.05), ** (P < 0.01) or *** (P < 0.001).
Results
Down-regulation of DAX-1 in HCC tissues or cells
First, DAX-1 expression was analyzed in 25 paired of HCC and adjacent non-tumor liver tissues using real-time PCR and western blot. As a result, our results showed that DAX-1 was significantly down-regulated in cancer tissues (Fig. 1A-1B) . To further determine the relationship between DAX-1 and HCC, several liver cell lines were analyzed. As show in in the Cellular Physiology and Biochemistry
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Fig . 1C and 1D , we also observed the lower expression of DAX-1 in three liver cancer cell lines (HepG2, Hep3B, and HuH-7), compared with normal liver cell line (THLE-3), indicating that DAX-1 expression was down-regulated in HCC tissues and cell lines.
Effect of DAX-1 on HCC cell proliferation
To elucidate the functional role of DAX-1 in the HCC development, adenoviruses containing DAX-1 or empty vector (EV) were transfected into Hep3B cells (Fig. 2A) . As shown in Figure 3B , DAX-1 overexpression led to a significant decrease in cell number of all cells tested (Fig. 2B) . Consistently, cell proliferation ability was also impaired by way of bromodeoxyuridine (BrdU) analysis (Fig. 2C) . Moreover, DAX-1 overexpression resulted in a significant increase in G0/G1 phase and decrease in S phase (Fig. 2D) . Similar results were also observed in HepG2 cells (Fig. 2E-2G) .
Next, small interfering RNA (siRNA) targeting DAX-1 gene or negative control was employed to knockdown endogenous DAX-1 expression in Hep3B cells (Fig. 3A) . As a result, down-regulation of DAX-1 led to a marked increase in cell number and proliferative ability in these cells (Fig. 3B-3C ). DAX-1 deficiency also resulted in a decrease in G0/G1 phase and increase in S phase (Fig. 3D) . Taken together, our results suggest that DAX-1 might be an important negative regulation of cell proliferation.
Effect of DAX-1 on HCC cell metastasis and invasion
Next, cell migration and invasion assays were carried out in Hep3B cells, which demonstrated that DAX-1 overexpression significantly inhibited, while its deficiency promoted the in vitro cell migration and invasion abilities (Fig. 4A-4D ).
DAX-1 overexpression inhibits tumor growth in vivo
To further investigate the function of DAX-1 on HCC growth in vivo, Hep3B cells with stable overexpression of DAX-1 were generated and injected subcutaneously into nude mice. The tumor growth was closely monitored for another 5 weeks. As compared with control, the 
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Cellular Physiology and Biochemistry tumor size and volume were markedly decreased in DAX-1-overexpressed tumors compared to control tumors (Fig. 5A -5B). The average tumor weight was also significantly increased (Fig. 5C) , suggesting that DAX-1 could suppress tumor growth in vivo. 
Discussion
Previous studies have shown that DAX-1 could act as a corepressor for several transcription factors and nuclear receptors. For instance, DAX-1 could inhibit hepatic gluconeogenic enzyme gene expression through negatively regulating the activity of hepatocyte nuclear factor 4 (HNF4) [13] . Besides, DAX-1 was shown to interact with liver X receptor (LXR) and farnesoid X receptor (FXR) to regulate hepatic triglyceride and bile acid metabolism, respectively [14, 15] . A recent study also suggest that DAX-1 participated in the acetaminophen (APAP)-induced hepatotoxicity through regulation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) [16] . Therefore, the roles and molecular mechanisms of DAX-1 in livers might be diverse and complicated, which remains to be explored in the future.
In the present study, our findings uncovered an important role for DAX-1 in controlling HCC development via regulating β-Catenin activity, suggesting that DAX-1 might be a tumor suppressor in the HCC development. The nuclear localization and activation of β-catenin represents the common hallmark in various human caner tissues [17] . Usually, β-catenin activity is tightly regulated by a multi-protein complex, including the tumor suppressor APC, the scaffolding protein Axin, and the phosphokinases GSK-3β [18] . Upon activation, the complex is destabilized, allowing for cytoplasmic β-catenin retention with subsequent nuclear translocation [19] . Previous reports have demonstrated that the repressive roles of DAX-1 required the corepressor NCOR and histone deacetylase (HDAC) [20, 21] . Therefore, we speculate that DAX-1 might inhibit β-catenin transcriptional activity through recruitment of these corepressors. However, the precise roles and mechanisms of DAX-1 in HCC need to be further investigated using other models, such as liver-specific DAX-1 knockout mice.
In summary, our data provide the evidence that DAX-1 could inhibit HCC cell growth in vitro and in vivo, implicating an important role of DAX-1 and suggesting that it might be a potential therapeutic strategy for HCC.
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